Good MorningEquity markets advanced on Tuesday, putting the S&P 500 at an all-time closing high. The move signals the market's willingness to continue the uptrend and may be a precursor to much higher price points. With earnings growth expected in 2025 and the potential for economic tailwinds to form by mid-year, the S&P 500 could sustain a rally through the end of 2025.
The stock rally is broadening. New highs in the Dow Jones Industrial Average, the Transportation Average, and the Russell 200 foreshadowed the move in the S&P. The move into other areas of the economy and small caps is a good sign but spells bad news for the previous market leaders. Names like NVIDIA, Amazon, Meta Platforms, and Microsoft may have difficulty setting new highs until sometime next year when sector rotation is completed. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Technology | |
Shares of Microsoft Corp (NASDAQ: MSFT) have been a cornerstone of tech portfolios for many years now, and 2024 has done little to tarnish that reputation. The stock is up a solid 15% year-to-date, and while it's struggled to push past July's all-time high, there are several reasons for investor... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
Donald Trump hasn't been shy about imposing tariffs when he returns to the White House in 2025. He has stated his intentions to levy 10% to 20% tariffs on imports and up to 60% to 100% tariffs on Chinese goods. Whether to take these statements literally or consider them negotiation tactics remains... Read the Full Story |
|
Healthcare | |
Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials. Health insurance companies, Congress, and patients love generics. ... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | |
The Russell 2000 Index, often called the small-cap index, is up about 19.6% in 2024. Much of that gain has come in the last six months, and the clarity after the U.S. presidential election is stirring animal spirits in the sector.
The bull case for small-cap stocks comes from lower interest rate... Read the Full Story |
|
Technology | |
The artificial intelligence (AI) revolution and cloud computing recovery are driving the worldwide growth of data centers. Existing data centers are furiously upgrading their systems to handle AI workloads, while new data centers are being built with AI deployment in mind. These AI data centers ar... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Markets | |
Wall Street's sleigh bells are starting to ring, signaling the arrival of the historically bullish period encompassing Thanksgiving, the Santa Claus Rally, and the January Effect. While the "Year-End Rally" often captures headlines, the market's trajectory during this festive season is shaped by a... Read the Full Story |
|
Materials | |
Some of the world’s best hedge funds and trading desks on Wall Street employ a simple strategy, one that is focused on the concept of relative valuation between two assets. In today’s market, the basic materials sector has shown a potential price widening between two widely followed pr... Read the Full Story |
|
Healthcare | | Semler Scientific, Inc. (NASDAQ: SMLR) has been one of November’s hottest stocks, soaring over 130% as investors rally behind its newfound embrace of Bitcoin. The healthcare and medical devices company recently made waves by significantly expanding its Bitcoin holdings and introducing "Bitcoin... Read the Full Story |
|
Technology | |
Cerence (NASDAQ: CRNC) is an AI stock that has burst onto the radar of many investors lately. Since its latest earnings release on Nov. 21, shares have skyrocketed 155% as of the Nov. 25 close. So, what does this company do, and why am I mentioning it in the same breath as the lauded SoundHound AI... Read the Full Story |
|
Markets | |
When the biggest minds on Wall Street decide to make a significant move in their portfolios, retail investors better pay attention and attempt to reverse engineer the thinking and reasoning behind these moves. Today, investors can look at the recent 13-F filings from the Oracle of Omaha himself, W... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts. | | View Today's Stock Pick |
|
